Faith C. Galderisi

Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia

M. Mori, L. Stork, James Z. Huang, 2009, Pediatric blood & cancer.

Hemorrhagic disease of the newborn despite vitamin K prophylaxis at birth

V. Flood, L. Boshkov, S. Lowas, 2008, Pediatric blood & cancer.

Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

J. Friedberg, P. Flynn, B. Holkova, 2018 .

Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant

R. Dinavahi, Aditi Mehta, S. Prockop, 2021, Blood.

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

K. Kelly, T. Leblanc, L. Brugières, 2018, Blood.